A nationwide, cross-sectional, web-based survey on healthcare providers' knowledge about, attitudes toward, and perceived barriers to adherence to clinical practice guidelines for anticancer drug therapy for older patients with cancer in Japan

Cancer Statistics, 2022 Cancer Statistics, 2022 Sedrak, 2021, Older adult participation in cancer clinical trials: a systematic review of barriers and interventions, CA Cancer J Clin, 71, 78, 10.3322/caac.21638 Mohile, 2018, Practical assessment and Management of Vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology, J Clin Oncol, 36, 2326, 10.1200/JCO.2018.78.8687 Guyatt, 2008, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, Bmj., 336, 924, 10.1136/bmj.39489.470347.AD Institute of Medicine Committee to Advise the Public Health Service on Clinical Practice G. In: Field MJ, Lohr KN, editors. Clinical Practice Guidelines: Directions for a New Program. Washington (DC): National Academies Press (US) Copyright © National Academy of Sciences.; 1990. Fischer, 2016, Barriers and strategies in guideline implementation-a scoping review, Healthcare (Basel), 4 Pathman, 1996, The awareness-to-adherence model of the steps to clinical guideline compliance. The case of pediatric vaccine recommendations, Med Care, 34, 873, 10.1097/00005650-199609000-00002 Cabana, 1999, Why don’t physicians follow clinical practice guidelines? A framework for improvement, Jama., 282, 1458, 10.1001/jama.282.15.1458 Brouwers, 2004, Clinicians’ assessments of practice guidelines in oncology: the CAPGO survey, Int J Technol Assess Health Care, 20, 421, 10.1017/S0266462304001308 Brouwers, 2009, Clinicians’ evaluations of, endorsements of, and intentions to use practice guidelines change over time: a retrospective analysis from an organized guideline program, Implement Sci, 4, 34, 10.1186/1748-5908-4-34 Damschroder, 2009, Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science, Implement Sci, 4, 50, 10.1186/1748-5908-4-50 Wild, 2005, Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation, Value Health, 8, 94, 10.1111/j.1524-4733.2005.04054.x Wildiers, 2014, International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer, J Clin Oncol, 32, 2595, 10.1200/JCO.2013.54.8347 Tucci, 2015, Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the lymphoma Italian foundation (FIL), Leuk Lymphoma, 56, 921, 10.3109/10428194.2014.953142 Tucci, 2009, A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy, Cancer., 115, 4547, 10.1002/cncr.24490 Spina, 2012, Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma, Oncologist., 17, 838, 10.1634/theoncologist.2011-0417 Hashiguchi, 2020, Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer, Int J Clin Oncol, 25, 1, 10.1007/s10147-019-01485-z Yothers, 2011, Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses, J Clin Oncol, 29, 3768, 10.1200/JCO.2011.36.4539 Tournigand, 2012, J Clin Oncol, 30, 3353, 10.1200/JCO.2012.42.5645 Twelves, 2012, Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy, Ann Oncol, 23, 1190, 10.1093/annonc/mdr366 Cameron, 2017, 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial, Lancet., 389, 1195, 10.1016/S0140-6736(16)32616-2 Slamon, 2011, Adjuvant trastuzumab in HER2-positive breast cancer, N Engl J Med, 365, 1273, 10.1056/NEJMoa0910383 Perez, 2014, Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831, J Clin Oncol, 32, 3744, 10.1200/JCO.2014.55.5730 Nishijima, 2019, Landscape of education and clinical practice in geriatric oncology: a Japanese nationwide survey, Jpn J Clin Oncol, 49, 1114, 10.1093/jjco/hyz123